Editas Medicine

Editas is a leading genome editing company and part of a transformational new area of health care – genomic medicine. The company was founded by the pioneers and world leaders in genome editing bringing specific expertise in CRISPR/Cas9 and TALENs technologies. The company’s mission is to translate its proprietary technology into novel solutions to treat a broad range of genetically-driven diseases.

Editas raised a $95M IPO in 2016 and began trading under the ticker symbol “EDIT.”


Company Profile

Editas Medicine Logo

Flagship Partners:

  • Doug Cole, Managing Partner